Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -65.99% is in line with its 1-year average of -70.64%, near the high end of its 1-year range (-144.96%–-35.16%).
As of the fiscal period ended Tuesday, June 30, 2026. 2.97% above its 12-month average of -68.01%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -65.99%.
RETURN ON EQUITY (ROE)
-65.99%
RETURN ON EQUITY (ROE) AVG TTM
-68.01%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+2.97%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-57.07%
vs the sector median at left
MapLight Therapeutics, Inc.
Market Cap
$414.45M
Return on Equity (ROE)
-65.99%
TTM Avg
-68.01%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$415.78M
Return on Equity (ROE)
-69.06%
TTM Avg
36.89%
3Y Avg
36.89%
5Y Avg
36.89%
Market Cap
$416.69M
Return on Equity (ROE)
-121.12%
TTM Avg
180.84%
3Y Avg
-1331.02%
5Y Avg
-839.91%
Market Cap
$413.16M
Return on Equity (ROE)
14.40%
TTM Avg
1.26%
3Y Avg
-7.83%
5Y Avg
-9.02%
Market Cap
$409.04M
Return on Equity (ROE)
-51.17%
TTM Avg
-29.16%
3Y Avg
-33.45%
5Y Avg
-16.04%
Market Cap
$408.28M
Return on Equity (ROE)
-77.06%
TTM Avg
-61.48%
3Y Avg
-56.03%
5Y Avg
-55.28%
Market Cap
$406.55M
Return on Equity (ROE)
-43.14%
TTM Avg
2.19%
3Y Avg
15.11%
5Y Avg
15.11%
Market Cap
$423.83M
Return on Equity (ROE)
-15.33%
TTM Avg
-56.08%
3Y Avg
-39.28%
5Y Avg
-33.86%
Market Cap
$403.77M
Return on Equity (ROE)
-37.05%
TTM Avg
-58.80%
3Y Avg
-40.96%
5Y Avg
-32.01%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MapLight Therapeutics, Inc. (MPLT) | $414.45M | -65.99% | -68.01% | N/A | N/A |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $415.78M | -69.06% | 36.89% | 36.89% | 36.89% |
| Senseonics Holdings, Inc. (SENS)vs › | $416.69M | -121.12% | 180.84% | -1331.02% | -839.91% |
| Strata Critical Medical, Inc. (SRTA)vs › | $413.16M | 14.40% | 1.26% | -7.83% | -9.02% |
| Neurogene Inc. (NGNE)vs › | $409.04M | -51.17% | -29.16% | -33.45% | -16.04% |
| Rezolute, Inc. (RZLT)vs › | $408.28M | -77.06% | -61.48% | -56.03% | -55.28% |
| Carlsmed, Inc. (CARL)vs › | $406.55M | -43.14% | 2.19% | 15.11% | 15.11% |
| Prothena Corporation plc (PRTA)vs › | $423.83M | -15.33% | -56.08% | -39.28% | -33.86% |
| Myriad Genetics, Inc. (MYGN)vs › | $403.77M | -37.05% | -58.80% | -40.96% | -32.01% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $403.34M | -80.96% | -47.93% | -34.61% | -20.56% |
ROE
-66.0%
ROA
-62.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -65.99% |
| 2026-03-31 | -49.89% |
| 2025-12-31 | -35.16% |
| 2025-09-30 | -44.04% |
| 2025-06-30 | -144.96% |
| 2025-03-31 | -87.08% |
| 2024-12-31 | -67.35% |
